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Neural tube defects (NTDs) are the second most common birth defects (1 in 1000 live births) in the world.
Periconceptional maternal folate supplementation reduces NTD risk by 50–70%; however, studies of folate
related and other developmental genes in humans have failed to definitively identify a major causal gene
for NTD. The aetiology of NTDs remains unknown and both genetic and environmental factors are
implicated. We present findings from a microsatellite based screen of 44 multiplex pedigrees ascertained
through the NTD Collaborative Group. For the linkage analysis, we defined our phenotype narrowly by
considering individuals with a lumbosacral level myelomeningocele as affected, then we expanded the
phenotype to include all types of NTDs. Two point parametric analyses were performed using VITESSE and
HOMOG. Multipoint parametric and nonparametric analyses were performed using ALLEGRO. Initial
results identified chromosomes 7 and 10, both with maximum parametric multipoint lod scores (Mlod)
.2.0. Chromosome 7 produced the highest score in the 24 cM interval between D7S3056 and D7S3051
(parametric Mlod 2.45; nonparametric Mlod 1.89). Further investigation demonstrated that results on
chromosome 7 were being primarily driven by a single large pedigree (parametric Mlod 2.40). When this
family was removed from analysis, chromosome 10 was the most interesting region, with a peak Mlod of
2.25 at D10S1731. Based on mouse human synteny, two candidate genes (Meox2, Twist1) were
identified on chromosome 7. A review of public databases revealed three biologically plausible candidates
(FGFR2, GFRA1, Pax2) on chromosome 10. The results from this screen provide valuable positional data
for prioritisation of candidate gene assessment in future studies of NTDs.
T
he second most common severely disabling birth defects
(1 in 1000 live births) in the world are neural tube
defects (NTDs), with the highest reported incidence rates
being in northern China (3.7 per 1000 live births) and in
Ireland (1.0 per 1000 live births). In the USA, incidence
increases from the west to the east coast, with the highest
rates seen in the Appalachian region.
NTDs result from a failure of neurulation, which occurs
around the 28th day after conception, at a time when most
women do not know they are pregnant. There are three
principal forms: anencephaly, encephalocele, and spina bifida
cystica (open spina bifida). Anencephaly is lethal in all cases.
Patients with encephalocele may survive but are mentally
retarded. Thus, the vast majority of patients seen have spina
bifida cystica, which manifests as an open spinal lesion
containing spinal tissue, resulting in abnormal innervation
beneath the level of lesion, varying degrees of muscle
weakness and sensory impairment, and a neurogenic bladder
and bowel.
Neural tube defects are caused by a complex interaction
between genes and the environment. Several lines of
evidence suggest a genetic component to NTDs. Firstly, the
estimated recurrence risk in siblings is 2–5%, giving a ls value
in NTD families of 25–50, representing up to a 50 fold
increased risk over that observed in the general population.1
This risk is increased to 4% for offspring of a person with an
NTD. Khoury et al have shown that for a recurrence risk to be
this high, an environmental teratogen would have to increase
the risk at least 100 fold to exhibit the same degree of
familial aggregation, indicating that a genetic component is
required.2 Additionally, estimates from small twin studies
indicate a higher concordance rate in monozygotic twins of
7.7% compared to 4.0% for dizygotic twins.3 4 NTDs are also
commonly associated with other known genetic disorders
including trisomy 13 and 18, Meckel-Gruber syndrome, and
chromosomal rearrangements.5 6
In familial cases, NTDs tend to breed true within families;
in other words, recurrences in families in which the proband
is affected with spina bifida tend to be also spina bifida, and
recurrences in families in which the case is anencephalic tend
to be also anencephalic.7–11 However, 30–40% of recurrences
involve an NTD phenotype that is different from the proband
phenotype. This intrafamily heterogeneity may represent the
pleiotropic effect of a common underlying gene, or may
suggest that in families with different phenotypic presenta-
tions, various forms of NTDs result from different underlying
genes.
The most substantial environmental risk factor for NTDs is
insufficient periconceptional maternal folate consumption.
Adequate folate supplementation reduces NTD recurrence
risk by 50–70%,12–14 yet the recurrence risk is not entirely
eliminated,15 suggesting that additional genetic factors are
responsible for the development of NTDs. To date, most
genetic studies in humans have focused on evaluating folate
related candidate genes, genes in early developmental path-
ways, and genes from mouse models (reviewed in Juriloff
Abbreviations: AD, Alzheimer’s disease; GDA, Genetic Data Analysis
program; HD, Hirschsprung’s disease; Hetlod, heterogeneity lod score;
HWE, Hardy-Weinberg equilibrium; Mlod, multipoint lod score; NTD,




and Harris16 and Copp et al17). Despite extensive efforts, the
assessment of candidate genes in NTDs has yet to identify a
major causative gene. An alternative approach of using
linkage analysis to identify positional candidates in multiplex
NTD pedigrees is hampered by lethality in anencephaly cases,
the increased mortality associated with spina bifida, and
termination of prenatally detected affected pregnancies.18 19
As a result, a full genomic screen in neural tube defects has
not been previously reported.
In the present article, we describe the results of the first
genomewide screen of 44 multiplex NTD families collected
from a national collaborative ascertainment effort. The data
presented represent valuable positional information to assist
prioritisation of candidate gene assessment in future studies
of neural tube defects.
MATERIALS AND METHODS
Clinical data collection
Probands were identified from a variety of sources including
myelodysplasia clinics, annual meetings of the Spina Bifida
Association of America (SBAA), and the worldwide web.
Ascertainment was carried out by researchers as part of the
NTD Collaborative Group (details at end of paper). All
individuals identified in this manner were included in the
study, and additional information was gathered to confirm
their diagnoses. First degree relatives and relatives connect-
ing related affected individuals in extended families were
also ascertained. Detailed family histories were obtained and
medical records, including operative reports and presurgical
x ray films, were collected for review of diagnosis by
neurosurgeons. Study staff trained in phlebotomy obtained
blood samples from affected individuals and related family
members at medical centres, clinics, or by visiting partici-
pants’ homes. In some cases, participants were sent kits by
post. The study was overseen by the Duke University Medical
Center institutional review board and informed consent was
obtained from all participants.
Genotyping methods
DNA was extracted from whole blood using the Puregene
system (Gentra Systems, Minneapolis, MN, USA). The DNA
samples from study subjects were organised into lists with a
standardised order of samples for which the technician was
blinded to sex and family composition, with quality control
(QC) standards incorporated at specified slots in the list. DNA
samples were aliquoted into 96 well plates and genotyping
performed using the fast automated angle scan technique
method.20 Multiplex reactions using two colour fluorescence
were used to increase the efficiency, lower the cost, and
significantly increase the speed of the genomic screen.21
To minimise systematic errors due to sample switches, gel
loading or running problems, or reading errors in the
genotyping procedures, QC samples were added to each gel
analysed in the laboratory that by virtue of their positioning
ensured they would cover a majority of possible technical
errors. In addition to genotyping two control individuals from
the Centre d’Étude du Polymorphisme Humain, who were
common to all gels, QC samples representing randomly
selected duplicated individuals from the dataset were
included to allow both within and between gel comparisons;
six QC samples were selected per 84 samples analysed. The
laboratory technician was blinded to the identity of the QC
samples. Data for marker genotypes were managed using the
PEDIGENE system22 in preparation for analysis. Before
merging genotypic data into PEDIGENE, agreement between
the QC genotype and the corresponding sample genotype was
assessed. With these procedures in place, 353 of 402 markers
attempted (88%) were approved for analysis. These 353
markers had all QC inconsistencies resolved and affected
genotypes were re-read. The mean genotyping efficiency over
all 353 markers was 96.9%.
Error checking
Mendelian pedigree inconsistencies were identified using
PEDCHECK23 and checked by laboratory technicians who
were blinded to the pedigree structure. Further verification of
interfamilial and intrafamilial genetic relationships was
performed using RELPAIR;24 25 at the beginning of the study
using the first 50 genotyped markers, and then later using all
353 genotyped markers.
Linkage analyses
Because of the genetic complexity of NTDs, we used a
multifaceted analytic strategy and performed both parametric
and nonparametric linkage analysis. Single point parametric
linkage analysis was conducted using VITESSE,26 under
dominant and recessive models for affected patients only,
and allowing for a disease allele frequency of 0.001. These
two point lod scores were used to calculate genetic hetero-
geneity lod scores (Hetlod scores) using HOMOG.27
Power analyses of the multiplex families in the screen were
carried out using SIMLINK28 29 allowing for a dominant
model and a disease allele frequency of 0.001. When fully
informative, the families were capable of generating an
estimated combined mean lod score of 4.745 at h=0.05
(SE=0.05; maximum 10.04) under the broad analysis
scheme, and a combined mean lod score of 3.7 at h=0.05
(SE=0.05; maximum 7.51) under the narrow analysis
scheme. These results are driven primarily by the existence
of a large family in which four affected individuals, mostly
related as cousins, are available. When a heterogeneity model
that allowed for 50% between pedigree heterogeneity was
used, the families were capable of generating an estimated
combined mean lod score of 1.34 at h=0.05 (SE=0.04;
maximum 8.34) under the broad analysis scheme.
Multipoint parametric and nonparametric linkage analyses
were performed using ALLEGRO.30 Genetic marker distance
was based on 10 cM sex average integrated maps from
deCode Genetics31 and the Marshfield Medical Research
Foundation maps. Map order was verified using Map-O-
Mat.32 Marker allele frequencies were estimated from our
dataset using all individuals.33 As our sample was comprised
of pedigrees of varying size, we assessed identity by descent
sharing (lod*) between all pairs of affected individuals within
a family using the Spairs sharing statistic
34 and the exponen-
tial model35 as implemented in ALLEGRO. The ALLEGRO
program calculates a full likelihood using affected but
unsampled individuals (see accompanying article), thus we
included ‘‘multiplex by history’’ pedigrees (n=8) in our
analyses. These families had one sampled affected person and
additional relatives with NTD who were unavailable for
sampling. We defined our most interesting regions as those
with maximum two point parametric Hetlod scores .2.0, or
multipoint parametric Hetlod or nonparametric lod* .1.3.
We refer to the maximum multipoint lod score, whether
parametric or nonparametric, as the Mlod.
Our dataset showed intrafamily phenotypic heterogeneity,
meaning that affected individuals within the same family
sometimes had different types of NTD. This might suggest
that the underlying causative genes for various forms of NTD
are different. To account for possible genetic heterogeneity in
our sample, we established two phenotype definitions for
NTD. The narrow phenotypic definition classified as affected
only those individuals presenting with the most common
type of NTD—that is, spina bifida with the lesion located at
the lumbosacral level (lumbosacral myelomeningocele). The
phenotype was then expanded to include all families in
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which two or more individuals had an NTD, regardless of
phenotypic presentation (broad phenotype definition).
We excluded all cases of spina bifida occulta from our
analyses. Additionally, in pedigrees with monozygotic twins,
we excluded one twin from each pair in the analysis. Using
this criterion, one monozygotic twin in pedigree 8836 was
removed. The majority of families in our sample were white
(n=41), but two families were Hispanic and one had mixed
with African American and white ethnicity. We performed
the genome screen using all families, and then re-analysed
the data using only the white families.
RESULTS
Following data cleaning, 44 families and 292 samples
(table 1) were included in the genomic screen analysis,
consisting of 21 sampled affected full sibling pairs, 12
sampled affected avuncular pairs, and 35 other affected
relative pairs. In total, there were 89 sampled affected
individuals, the majority of whom had lumbosacral myelo-
meningocele (n=50). After exclusion of one monozygotic
twin, 49 sampled individuals with lumbosacral myelomenin-
gocele were included in the analysis. The remaining affected
individuals had other forms of NTD including anencephaly,
cervical myelomeningocele, craniorachischisis, encephalo-
cele, lipomyelomeningocele, rachischisis, and thoracic mye-
lomeningocele. Seventeen of these pedigrees were
informative for the narrow phenotypic classification; mean-
ing that at least two affected individuals had lumbosacral
myelomeningocele. Three of these pedigrees were ‘‘multiplex
by history’’ families.
Results from linkage analysis using all 44 families
compared with the 41 white families only were similar, so
we combined the results. Fig 1 shows the maximum two
point lod scores for all 353 markers arranged in map order
under narrow and broad phenotypic definitions. The best two
point lod scores were on chromosome 7p22 with a score of
2.31 at D7S513 and at 11p15 with a score of 2.44 at
D11S2362. Parametric and nonparametric multipoint linkage
results (Mlod .1.3), under both phenotype definitions, are
summarised in table 2. For simplification, only multipoint
results for the dominant model are presented for the
parametric analyses. Five regions of interest were identified
from these analyses: chromosomes 7p22, 10q25.3, 11p15,
15q26, and 21q22.11. The best multipoint peak fell in the
24 cM interval spanned by D7S3056 and D7S3051, producing
a parametric Mlod score of 2.45 (fig 2A) under the broad
phenotype, and demonstrating consistent linkage evidence
(Mlod .1.3) across all analyses. Chromosome 10 achieved a
parametric Mlod score of 2.08 under the broad phenotype
(D10S1731 at 134.96 cM) (fig 2B). The best linkage peak for
chromosome 11 (Mlod 1.51) fell between D11S2362 and
D11S1999 (fig 2C), using the broad phenotype and a
nonparametric analytic approach. Chromosome 15 produced
a parametric Mlod score of 1.46 under the narrow classifica-
tion, between D15S127 and D15S652 (fig 2D). Chromosome
21 had a peak Mlod score of 1.44 at D21S1270 (fig. 2E) under
the narrow phenotype.
Our strongest linkage evidence based on two point and
multipoint analyses was on chromosome 7. However, as the
multipoint peak fell around the most telomeric marker typed
(D7S3056), we genotyped additional single nucleotide poly-
morphisms (SNPs) in the region to verify our findings. We
selected "assay on demand" SNPs (Applied Biosystems)
having a minimum allele frequency .0.30. We analysed 13
SNPs (table 3), four of which are located distal to the most
telomeric marker D7S3056. Deviations from Hardy-Weinberg
equilibrium (HWE) (p,0.06) were tested using the Genetic
Data Analysis (GDA) program.36 Two markers (HCV8511072,
RS852423) were not in HWE, hence pairwise linkage
disequilibrium (LD) was calculated for all markers using
the composite LD measure as implemented in GDA, which
does not assume HWE.
Because current implementations of multipoint linkage
analysis are unable to account for intermarker LD, the least
informative marker in a pair of markers in LD was excluded
from the multipoint analysis. Thus, HCV8511072 and
RS852423, which were in LD with RS1636166 (p=0.002)
and RS1470539 (p=0.06), respectively, were eliminated
from further analysis. With the addition of the SNPs to the
original microsatellite marker data, we were able to confirm
that our linkage peak mapped to marker D7S641 located
17.41 cM from the telomere (Mlod 2.49 under the broad
phenotype; Mlod 2.09 under the narrow phenotype).
An examination of family specific parametric scores
identified a single pedigree (family 8776) primarily con-
tributing to the linkage results on chromosome 7. Under the
broad phenotype, family 8776 produced an Mlod score of 2.40
at marker D7S513 located 22.6 cMs from pter. Under the
narrow phenotype, which in this family led to the exclusion
of an individual affected with a fatty filum (100), family 8776













Total no. of sampled individuals 292 123
Sampled affected individuals 89 34
Sampled male participants 138 59
Sampled female participants 154 64
Affected sibling pairs 21 9
Affected half sibling pairs 2 0
Affected avuncular pairs 12 3
Affected first cousin pairs 11 4
Affected second cousin pairs 2 2
Affected relative pairs .2nd degree 20 6
*Includes families with at least two affected individuals with any type of
NTD; all individuals with an NTD coded as affected. Families having at
least two affected individuals with lumbosacral myelomeningocele; only
individuals with lumbosacral myelomeningocele coded as affected.
























Figure 1. Two point maximum parametric lod scores, allowing for
genetic heterogeneity (Hetlod). Results for all 353 markers typed are
shown for four analytic schemes: broad phenotype (n =44) assuming a
dominant genetic model (¤), narrow phenotype (n = 17) assuming a
dominant genetic model (&), broad phenotype (n =44) assuming a
recessive genetic model (m), and narrow phenotype (n =17) assuming a
recessive genetic model (6).
942 Rampersaud, Bassuk, Enterline, et al
www.jmedgenet.com
produced an Mlod of 2.10 at marker D7S513. Fig3 shows
segregation of a shared disease haplotype (solid black bars)
among affected individuals, spanning a 20 cM interval
flanked by markers D7S3056–D7S2557. A crossover between
D7S641 and D7S2201 occurs in individual 0126, an unaf-
fected member of the pedigree, and potentially narrows the
shared region to the 9 cM interval between D7S3056 and
D7S641.
To further confirm that family 8776 was indeed driving the
parametric linkage results, we removed the pedigree from the
dataset and reran the analysis using the remaining 43



















































































































































































































































































































































































































Figure 2 Multipoint lod score curves for Mlod .1.3 from chromosomes: (A) 7, (B) 10, (C) 11, (D) 15, and (E) 21 under the broad (44 families) and
narrow (17 families) phenotypic classification. Parametric Hetlod scores and nonparametric sPairs lod* are shown. Marker names and positions are
given at the top of each graph.
Table 2 ALLEGRO multipoint lod scores .1.3 for parametric (dominant model) and
nonparametric linkage analyses using a broad and a narrow phenotype criteria for all
families and after removal of family 8776
Cytogenetic band Chromosomal region
Parametric* Nonparametric
Broad Narrow Broad Narrow
Complete dataset
7p22 d7s3056-d7s3051 2.45 2.06 1.89 1.72
10q25.3 d10s1731 2.08 1.44 – 1.54
11p15 d11s2362-d11s1999 – – 1.51 –
15q26 d15s127-d15s652 – 1.46 – 1.41
21q22.11 d21s1270 1.31 – 1.43 1.44
Without family 8776
10q25.3 d10s1731 (134.96 cM) 2.25 1.78 (1.2) 1.73
11p15.4 d11s2362 (7.27 cM) – – 1.32 –
15q26.1 d15s652 (99.92 cM) – 1.77 – –
21q22.11 d21s1270 (31.83 cM) 1.38 – 1.32 –
*Parametric Hetlod scores; pairs scoring statistic under an exponential model. cM, DECODE cm. n = 44 for broad
phenotype and n =17 for narrow phenotype in the complete dataset; n = 43 and n =16 for broad and narrow,
respectively, without family 8776.
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most significant region was on chromosome 10 with a
parametric Mlod score of 2.25 at 134.96 cM at D10S1731
under the broad phenotype definition (table 2). While still of
interest, the lod scores for chromosomes 11 and 21 were
somewhat reduced. The region on chromosome 11 produced
a nonparametric Mlod score of 1.32 at 7.27 cM, under the
narrow phenotype. The region on chromosome 21 produced a
parametric Mlod of 1.38 and a nonparametric Mlod of 1.32 at
31.83 cM, under the broad phenotype. Chromosome 15 had a
slightly higher Mlod score of 1.77 at D15S652 under the
narrow phenotype. Furthermore, our results showed that
after this family was excluded, no evidence in favour of
linkage remained on chromosome 7 (Mlod,1.0).
DISCUSSION
Genomic screens using traditional linkage analysis
approaches are dependent on the availability of multiplex
pedigrees; most genomic screens are large, with more than
100 families included.37 38 However, screens of as few as 31–
80 pedigrees have identified regions of interest in complex
disease. Importantly, the initial genomic screen in late onset
Alzheimer disease included only 31 multiplex pedigrees,38 yet
identified a region of interest on chromosome 19 that was
subsequently found to harbour ApoE, a major susceptibility
gene for Alzheimer disease. In systemic lupus erythematosus,
14 pedigrees with 34 affected individuals identified a lod
score of 6.2 in a region on chromosome 15.39 Thus, small
sample sizes in genomic screens can identify regions of
interest when the genetic effect is strong. In NTDs, samples
from affected individuals in multiplex families can be
difficult to obtain because of the high mortality associated
with the condition and terminations of affected pregnancies.
Thus, no other genome wide screens in NTD have been
reported.
Additionally, in some common complex diseases, identifi-
cation of rare families demonstrating mendelian or near-
mendelian inheritance patterns has led to the identification
of important loci through traditional linkage analysis
approaches. Classic examples of such diseases are
Alzheimer’s disease (AD),40 breast cancer,41 and
Hirschsprung’s disease42 (HD). This approach can potentially
identify mendelian forms of the disease that present
phenotypically the same as non-mendelian forms, such as
in AD and breast cancer. In those disorders, the identified loci
were specific to a mendelian subset of the disease and did not
extend to the sporadic non-mendelian forms. Alternatively,
susceptibility genes mapped in multiplex families may also be
found to increase risk for the common non-mendelian forms
of a disease, as is the case with HD.
In this report of a microsatellite based genome screen of 44
multiplex NTD families, the most significant linkage result
was on chromosome 7, which produced consistently high lod
Table 3 Physical map location of SNPs used to
verify chromosome 7 linkage signal.
Microsatellite marker locations (bold) are also
shown for reference
Marker name Position (bp)*
RS1636166 2 685 704
RS1357310 3 196 845
HCV8511072 3 713 727
RS1470539 4 173 026
D7S3056 4 237 377
RS4720437 4 778 704
RS852423 5 278 704
D7S2201 5 374 993
RS2302334 5 778 704
HCV25632983 6 225 487
HCV3219225 6 832 651
RS1544465 7 329 057
RS12847 7 836 531
D7S641 8 458 102
RS886505 8 496 394
RS721689 8 967 586
D7S513 11 395 687
*Ensembl marker location; markers removed from analyses
















































































































































































































































































































































Figure 3 Pedigree diagram of family 8776 demonstrating segregation of the 184-113 haplotype in individuals affected with lumbosacral
myelomeningocele. Individual 0100 has a fatty filum (an NTD variant) and also carries the associated haplotype.
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scores across different analysis schemes (parametric, broad
phenotype Mlod 2.45; parametric, narrow phenotype Mlod
2.06; nonparametric, broad phenotype Mlod 1.89; nonpara-
metric, narrow phenotype Mlod 1.72). One family (8776) was
identified as primarily driving the linkage results on
chromosome 7 and appears to segregate a common region
on 7p22 among all affected individuals, including one
individual with an NTD variant, fatty filum. Using only
affected individuals, the region of interest spans 20 cM and is
flanked by markers D7S3056 and D7S2557. A crossover in an
unaffected individual (126) in this family allowed us to
potentially narrow the candidate region and restrict it to the
9 cM region between D7S3056 and D7S641. However, cross-
overs in unaffected individuals should be treated with
caution, as it is never clear whether the individual harbours
some phenotypic variant, undetected because it is asympto-
matic.
A review of public databases, using our internally devel-
oped DAS-Ensembl integration and locally developed
scripts,43 found 72 genes from NCBI and 63 ESTs from
Ensembl in the region surrounding our highest linkage peak
on chromosome 7 in family 8776, representing an unbiased
collection of genes based on positional linkage evidence.
While none of these is an obvious candidate for NTD,
evaluation of syntenic regions between the mouse and
human genomes (NCBI/OMIM Davis mouse to human
homology maps) reveals an additional two genes (Meox2,
Twist1) in regions on mouse chromosome 12 that are
homologous to human 7p21.1–22.2. Meox2 is a homeobox
gene that is expressed in the somites during neurulation,44
while mouse embryos homozygous for Twist1 have been
shown to develop neural tube defects.
When family 8776 was eliminated from the linkage
analysis, regions of interest on chromosomes 10, 11, 15,
and 21 were identified. The best linkage evidence was at
10q25.3, which produced a parametric multipoint lod score of
2.25. Three candidate genes (FGFR2, GFRA1, and Pax2) map
close to 10q25.3. Fibroblast growth factor receptor 2 (FGFR2)
is expressed in the spinal cord of the chick embryo in the
stages between gastrulation and limb bud formation.45 GDNF
family receptor alpha 1 (GFRA1) is expressed in embryonic
mouse spinal cord.46 Pax2 belongs to the Pax gene family,
long investigated for its role in relation to NTD.47–49
Several plausible NTD candidates map to the short arm on
chromosome 21 (CBS, RFC1, and NCAM2). Cystathionine
beta-synthase (CBS) and reduced folate carrier protein 1
(RFC1) are both important players in the folate metabolism
pathway.50 Recently, neural cell adhesion molecule 1
(NCAM1), which maps to 11q21.3, has been shown to be
associated in NTD singleton families,51 making the NCAM2
gene on chromosome 21 potentially interesting. No obvious
candidate genes in the regions on chromosomes 11 and 15
are apparent.
Our approach to evaluating these data will be to maximise
the amount of information we extract from the genomic
screen by carefully characterising regions of interest, con-
tinuing to add multiplex pedigrees as they become available,
expanding the phenotypic classifications to increase the
sample size, and integrating data from other important lines
of investigation involving biologically plausible candidate
genes, such as those from mouse models of NTDs and genes
involved in folate metabolism. These data represent an
important and useful tool for narrowing the search for
candidate genes for NTDs.
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